Citations

Clear

941 citation(s) found for "Tan, MH".

Diagnostic Challenge in a Patient with Severe Anion Gap Metabolic Acidosis
Kalimullah, Ejaaz A., Sohail, M. Rizwan , Ramar, Kannan , Tan, Eugene M. , Tan, E M

Mayo Clinic

Case Reports in Critical Care | May 31, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-3

10.1155/2015/272914 | PMID 26113997 Get It

The approach to the patient with acute renal failure and elevated anion and osmolal gap is difficult. Differential diagnoses include toxic alcohol ingestion, diabetic or starvation ketoacidosis, or 5-oxoproline acidosis. We present a 76-year-old female with type 2 diabetes mellitus, who was found at home in a confused state. Laboratory analysis revealed serum pH 6.84, bicarbonate 5.8 mmol/L, pCO2 29 mmHg, anion gap 22.2 mmol/L, osmolal gap 17.4 mOsm/kg, elevated beta-hydroxybutyrate (4.2 mmol/L), random blood sugar 213 mg/dL, creatinine 2.1 mg/dL, and potassium 7.5 mmol/L with no electrocardiogram (EKG) changes. Fomepizole and hemodialysis were initiated for presumed ethylene glycol or methanol ingestion. Drug screens returned negative for ethylene glycol, alcohols, and acetaminophen, but there were elevated urine levels of acetone (11 mg/dL). The acetaminophen level was negative, and 5-oxoproline was not analyzed. After 5 days in the intensive care unit (ICU), her mental status improved with supportive care. She was discharged to a nursing facility. Though a diagnosis was not established, our patient’s presentation was likely due to starvation ketosis combined with chronic acetaminophen ingestion. Acetone ingestion is less likely. Overall, our case illustrates the importance of systematically approaching an elevated osmolal and anion gap metabolic acidosis.
Evaluation of the FilmArray Blood Culture ID Panel on Biofilms Dislodged from Explanted Arthroplasties for Prosthetic Joint Infection Diagnosis
Vasoo, Shawn , Cunningham, Scott A. , Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Hanssen, Arlen D. , Osmon, Douglas R. , Berbari, Elie F. , Patel, Robin , Abdel, Matthew P. , Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | May 28, 2015 | Volume: 53 | Issue: 8 | Pages: 2790-2792

10.1128/jcm.01333-15 | PMID 26019200 Get It

Clinical Characteristics and Outcomes of Patients with and without Diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
MacDonald, Michael R. , She, Lilin , Doenst, Torsten , Binkley, Philip F. , Rouleau, Jean L. , Tan, Ru‐San , Lee, Kerry L., Miller, Alan B. , Szalewska, Dominika , Waclawiw, Myron A., Castelvecchio, Serenella , Adlbrecht, Christopher , Michler, Robert E. , Oh, Jae K. , Petrie, Mark C. , Sopko, George S. , Dąbrowski, Rafał , Velazquez, Eric J. , Petrie, Mark C

Mayo Clinic

European Journal of Heart Failure | May 26, 2015 | Volume: 17 | Issue: 7 | Pages: 725-734

10.1002/ejhf.288 | PMID 26011509 Get It

Abstract Aims Hypothesis 1 of the Surgical Treatment for Ischemic Heart Failure (STICH) trial enrolled 1212 patients with an LVEF of ≤35% and CAD amenable to coronary artery bypass grafting (CABG). Patients were randomized to CABG and optimal medical therapy (MED) or MED alone. The objective was to assess whether or not patients with diabetes mellitus (DM) enrolled in the STICH trial would have greater benefit from CABG than patients without DM. Methods and results The characteristics and clinical outcomes of patients with and without DM randomized to CABG and MED or MED alone were compared. DM was present in 40%. At baseline, patients with DM had more triple vessel CAD, higher LVEF, and smaller left ventricular volumes. In patients with DM, the primary outcome of all-cause mortality occurred in 39% of patients in the MED group and 39% in the CABG group [hazard ratio (HR) with CABG 0.96, 95% confidence interval (CI) 0.73–1.26]. In patients without DM, the primary outcome occurred in 41% of patients in the MED group and 32% in the CABG group (HR with CABG 0.80, 95% CI 0.63–1.02). While numerically it would appear that the treatment effect of CABG is blunted in patients with DM, there was no significant interaction between DM and treatment group on formal statistical testing. Conclusions Patients with DM enrolled in the STICH trial had more triple vessel disease, smaller hearts, and higher LVEF than those without DM. CABG did not exert greater benefit in patients with DM.
Primary Bone Tumors: Epidemiologic Comparison of 9200 Patients Treated at Beijing Ji Shui Tan Hospital, Beijing, China, With 10 165 Patients at Mayo Clinic, Rochester, Minnesota
Niu, Xiaohui , Xu, Hairong , Inwards, Carrie Y., Letson, G. Douglas , Bui, Marilyn M, Li, Yuan, Ding, Yi , Bui, Marilyn M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | May 15, 2015 | Volume: 139 | Issue: 9 | Pages: 1149-1155

10.5858/arpa.2014-0432-oa | PMID 25978765 Get It

Context Although primary bone tumors are extremely rare, the literature suggests that there are variations in the epidemiologic characteristics in different populations. The most frequently cited epidemiologic characteristics of primary bone tumors are derived from a large US series (Mayo Clinic), with no comparable study thus far performed in China. Objective To identify any potential epidemiologic differences between Chinese patients and a US series of patients. Design We performed a comparison study between 9200 patients treated at Beijing Ji Shui Tan Hospital (JST) and 10 165 patients treated at Mayo Clinic (MC), Rochester Minnesota. Detailed epidemiologic features were analyzed. Results We found that giant cell tumor and osteosarcoma have significantly higher incidences in the JST than the MC patients (P < .001). However, JST patients had a significantly lower incidence of Ewing sarcoma, chordoma, fibrosarcoma, myeloma, and malignant lymphoma (P < .001). For most benign and malignant bone tumors, the Chinese cohort had a more distinct male predominance than the US cohort. Malignant bone tumors had a monomodal age distribution in the JST patient group, with a bimodal age distribution in the MC cohort. Also, there were was a predilection for tumors of the femur and tibia among the JST patients (P < .001). Conclusions Our data confirm that epidemiologic variations of primary bone tumors exist in different populations. Factors that may contribute to these observed differences are proposed and discussed.
The prevalence of substance use disorders in American physicians
Oreskovich, Michael R., Sotile, Wayne M., Satele, Daniel , Sloan, Jeff, Boone, Sonja, Shanafelt, Tait D. , Dyrbye, Liselotte N. , Tan, Litjen , West, Colin P. , Sloan, Jeff A.

Mayo Clinic

The American Journal on Addictions | March 30, 2015 | Volume: 24 | Issue: 1 | Pages: 30-38

10.1111/ajad.12173 | PMID 25823633 Get It

Fever and Cardiac Arrest in a Patient With a Left Ventricular Assist Device
Tan, Eugene M. , Marcelin, Jasmine R , Tande, Aaron J. , Rizza, Stacey A. , Cummins, Nathan W. , Tande, Aaron , Tan, E M , Marcelin, Jasmine

Mayo Clinic

Open Forum Infectious Diseases | March 6, 2015 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/ofid/ofv033 | PMID 26380334 Get It

Abstract A 68-year-old avid deer hunter with ischemic cardiomyopathy underwent left ventricular assist device (LVAD) implantation for destination therapy two years ago. He was living an active lifestyle, tracking deer and fishing in a Midwestern forest in November. His wife removed an engorged tick on his thorax. A few days later, he experienced fever, confusion, and ataxia and was hospitalized with septic shock and ventricular fibrillation. The LVAD site had no signs of trauma, drainage, warmth, or tenderness. A peripheral blood smear revealed intraleukocytic anaplasma microcolony inclusions. After completing 14 days of doxycycline, he recovered. Typical non-device-associated infections in LVAD recipients include pneumonia, urinary tract infection, or Clostridium difficile colitis. Human granulocytic anaplasmosis (HGA) is a very atypical non-LVAD infection, and the incidence of tickborne illnesses in LVAD recipients is unknown.
The prevalence of substance use disorders in American physicians
Oreskovich, Michael R., Sotile, Wayne M., Satele, Daniel , Sloan, Jeff A. , Boone, Sonja, Shanafelt, Tait D. , Dyrbye, Liselotte N. , Tan, Litjen , West, Colin P.

Mayo Clinic

The American Journal on Addictions | November 20, 2014 | Volume: No volume available | Issue: No issue available | Pages: n/a-n/a

10.1111/j.1521-0391.2014.12173.x Get It

Klebsiella pneumoniae ST147 Coproducing NDM-7 Carbapenemase and RmtF 16S rRNA Methyltransferase in Minnesota
Lee, Chang‐Seop , Vasoo, Shawn , Patel, Robin , Doi, Yohei , Hu, Fupin , Patel, Robin , Doi, Yohei

Mayo Clinic

Journal of Clinical Microbiology | August 21, 2014 | Volume: 52 | Issue: 11 | Pages: 4109-4110

10.1128/jcm.01404-14 | PMID 25143576 Get It

Abstract 2271: Metformin pharmacogenomics: A genome-wide associate study to identify genetic and epigenetic biomarkers involved in metformin response.
Niu, Nifang, Tan, Xiang‐Lin, Schaid, Daniel J. , Abo, Ryan, Batzler, Anthony , Jenkins, Gregory D. , Badosa, Manel Esteller, Wang, Liewei , Fridley, Brooke L. , Carlson, Erin E. , Morán, Sebastián , Heyn, Holger

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 2271-2271

10.1158/1538-7445.am2013-2271 Get It

Abstract BACKGROUND Metformin, a widely used anti-diabetic drug, is being considered as a highly promising agent for treatment and prevention of many types of cancer, including breast cancer. Although the exact mechanism of action of metformin is unknown, it is thought that metformin is an AMPK activator. To better individualize metformin therapy and explore additional underlying molecular mechanism associated with metformin action, we conducted a metformin pharmacogenomic study using 266 genomic data-enriched lymphoblastoid cell lines (LCLs). METHODS Genome-wide microarray data were generated for all LCLs, including 1.3 million SNPs, 485K DNA methylation probes and 54K mRNA expression probe sets. Metformin cytotoxicity assay was performed using MTS assay. Genome-wide association (GWA) analyses and integrated analyses using all the genomic data and metformin cytotoxicity (IC50 value) were performed to identify top candidate genes for functional validation in breast cancer cell lines, MDA-MB 231 and Hs578T, using siRNA screening approach. Further mechanistic study was performed to investigate the role of candidates in regulation of AMPK activity. RESULTS GWA analyses in LCLs identified 198 mRNA expression probe sets and 210 DNA methylation probes associated with metformin IC50 with p-value <10-4, respectively. Analysis of 1.3 million SNPs found 12 loci (a region containing at least 1 SNP of p-value <10-5 and 1 SNP of p-value <10-3 within 50kb) that were associated with metformin IC50. Integrated SNP loci-mRNA expression-IC50 analysis indicated that the SNP loci on chromosome 16 was associated with metformin IC50 through a trans-regulation of expression of 7 genes with p-value <10-4. Integrated methylation-mRNA expression-IC50 analysis showed that 15 DNA methylation probes in 6 genes were associated with metformin IC50 through both cis- and trans-regulation of expression of 48 genes with p-value <10-4, including 4 methylation probes in 3 of those 6 genes that were cis-correlated with its own gene expression. Ingenuity pathway analysis of top 62 candidate genes identified four major pathways and 55 genes within those pathways were selected for functional validation in breast cancer cell lines. The knockdown experiment showed that down regulation of 25 genes significantly altered metformin sensitivity in MDA-MB231, and 14 of them also showed the same effect in Hs578T. Preliminary mechanistic experiment indicated that knockdown of 7 genes significantly reduced AMPK activity in MDA-MB231 and 3 of them had same effect in Hs578T. CONCLUSIONS GWAS using a genomic data-enriched LCL model system, together with functional validation in breast cancer cell lines, could help us to identify novel genetic and epigenetic biomarkers involved in metformin response and help us to better understand the mechanisms of metformin in cancer treatment. Citation Format: Nifang Niu, Xianglin Tan, Brooke L. Fridley, Daniel J. Schaid, Ryan P. Abo, Anthony Batzler, Erin E. Carlson, Gregory Jenkins, Sebastian Moran, Holger Andrea Heyn, Manel Esteller Badosa, Liewei Wang. Metformin pharmacogenomics: A genome-wide associate study to identify genetic and epigenetic biomarkers involved in metformin response. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2271. doi:10.1158/1538-7445.AM2013-2271